Philippe Camus, M.D.

Dijon, France

Both apps are now back!

Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

LX.b

Lymphoproliferative disease (pulmonary, endobronchial, endothoracic)

Publications

Rispal P, Lasseur C, Labouyrie E, Doutre MS, Pellegrin JL, Bernard P, Merlio JP, De Mascarel A, Leng B

[Pseudolymphoma induced by carbamazepine. Apropos of 2 cases].

La Revue de medecine interne 1995;16;214-8 — 1995 — 214-8

Sinnige HA, Boender CA, Kuypers EW, Ruitenberg HM

Carbamazepine-induced pseudolymphoma and immune dysregulation.

Journal of internal medicine 1990 May;227;355-8 — 1990 May — 355-8

Katzin WE, Julius CJ, Tubbs RR, McHenry MC

Lymphoproliferative disorders associated with carbamazepine.

Archives of pathology & laboratory medicine 1990 Dec;114;1244-8 — 1990 Dec — 1244-8